



Supplemental Figure 1 – Sequence of study events for each participant. Questionnaires – Neuropathic Pain Symptom Inventory; Brief Pain Inventory; Depression, Anxiety, and Positive Outlook Scale; Sleep Problems Index II. QST – quantitative sensory testing. AE – adverse events.

Table 1 – Baseline QST Parameters

Trait	Pregabalin then Placebo (n = 12)	Placebo then Pregabalin (n = 14)	Total (n = 26)
Mechanical pain threshold (g)	12.5 (412.9)	-24.6 (409.6)	-10.1 (388.6)
Mechanical detection threshold (g)	-2.6 (2.7)	-18.5 (61.1)	-11.2 (44.8)
Cold detection threshold (°C)	3.1 (4.6)	5.8 (8.1)	4.5 (6.7)
Warmth detection threshold (°C)	-6.2 (3.5)	-4.8 (3.2)	-5.5 (3.4)
Cold pain threshold (°C)	1.6 (13.2)	4.4 (11.3)	3.1 (12.1)
Heat pain threshold (°C)	-3.4 (4.7)	-2.4 (3.8)	-2.8 (4.2)
Vibration detection threshold	1.9 (1.7)	2.4 (1.5)	2.21 (1.6)
Wind-up ratio	-0.1 (1.1)	-0.6 (1.4)	-0.4 (1.2)
Conditioned pain modulation	-6.3 (12.2)	-1.6 (10.6)	-3.8 (11.4)

All parameters are listed as mean (standard deviation). All parameters were tested prior to the administration of the first study drug (day 0 of the study). Conditioned pain modulation is reported as the value at the affected site; all other parameters are reported as the difference between the affected site and the ipsilateral shoulder (control site).

Table 2 - Analgesic responses to pregabalin vs placebo as a function of baseline Neuropathic Pain Symptom Inventory Neuropathic Pain (NPSI) subscores

	Percent Reduction in Average Pain			P	Percent Reduction in Worst Pain			P
NPSI subscore	Pregabalin	Placebo	Difference		Pregabalin	Placebo	Difference	
<b>Burning</b>								
≥ 3 (n = 11)	26.7 (24.2)	8.3 (21.2)	18.3 (35.8)	0.44	24.9 (27.1)	11.5 (22.2)	13.4 (38.4)	0.78
< 3 (n = 12)	20.6 (23.3)	15.0 (33.6)	5.7 (41.8)		34.5 (20.6)	16.3 (34.8)	18.3 (42.1)	
<b>Pressing</b>								
≥ 3 (n = 8)	17.3 (16.9)	-1.05 (27.4)	18.4 (28.6)	0.51	20.8 (21.9)	2.7 (29.4)	18.2 (37.2)	0.85
< 3 (n = 15)	26.8 (26.2)	18.6 (26.6)	8.2 (43.7)		34.8 (24.2)	20.0 (27.7)	14.8 (42.0)	
<b>Paroxysmal</b>								
≥ 3 (n = 9)	19.8 (24.4)	1.4 (29.8)	18.4 (40.6)	0.53	22.3 (28.0)	5.8 (33.3)	16.5 (49.1)	0.96
< 3 (n = 14)	25.9 (23.3)	18.5 (25.6)	7.4 (38.4)		34.8 (20.5)	19.2 (25.6)	15.6 (34.1)	
<b>Evoked</b>								
≥ 3 (n = 13)	26.9 (25.7)	8.9 (22.9)	18.0 (31.2)	0.42	29.4 (27.4)	12.4 (25.0)	16.9 (34.9)	0.90
< 3 (n = 10)	19.1 (20.5)	15.6 (34.4)	3.6 (47.3)		30.7 (19.9)	16.0 (34.7)	14.7 (46.8)	
<b>Paresthesia/ Dysesthesia</b>								
≥ 3 (n = 20)	24.5 (23.2)	10.2 (27.0)	14.3 (36.4)	0.63	30.4 (25.4)	14.8 (30.7)	15.6 (42.3)	0.83
< 3 (n = 3)	16.7 (28.9)	22.2 (38.5)	-5.6 (58.65)		26.7 (11.5)	8.3 (14.4)	18.3 (13.2)	

P values shown for two-tailed, unpaired t-tests for difference in pain reduction for pregabalin vs placebo.